Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly

被引:131
作者
Stomrud, Erik [1 ]
Hansson, Oskar
Blennow, Kaj
Minthon, Lennart
Londos, Elisabet
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Clin Memory Res Unit, SE-20502 Malmo, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden
关键词
Alzheimer disease; early diagnosis; dementia; mild cognitive impairment; cerebrospinal fluid biomarker; Tau protein; beta-amyloid; 42;
D O I
10.1159/000105017
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples. Methods: In this study, 57 controls were tested for CSF biomarkers at baseline and then cognitively followed over 3 years. Results: Low levels of baseline beta-amyloid 1 - 42 (A beta 42) were associated with development of subjective memory impairment affecting quality of life (memQoL), with a worse Mini Mental Status Examination score and with inability to live in regular housing at follow-up ( p < 0.05). The combination of baseline A beta 42 and phosphorylated tau (P-tau) was found to predict development of pathological memQoL with a sensitivity of 71.4% and a specificity of 75.7 (< 0.01). Conclusion: Low A beta 42 and combined A beta 42 and P-tau predicted subjective cognitive decline in healthy individuals. In summary, this study shows that already in the clinically normal population Alzheimer-disease-related biological signs might be detectable. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 37 条
  • [21] Assessing quality of life in older adults with cognitive impairment
    Logsdon, RG
    Gibbons, LE
    McCurry, SM
    Teri, L
    [J]. PSYCHOSOMATIC MEDICINE, 2002, 64 (03): : 510 - 519
  • [22] Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease
    Maruyama, M
    Higuchi, M
    Takaki, Y
    Matsuba, Y
    Tanji, H
    Nemoto, M
    Tomita, N
    Matsui, T
    Iwata, N
    Mizukami, H
    Muramatsu, SI
    Ozawa, K
    Saido, TC
    Arai, H
    Sasaki, H
    [J]. ANNALS OF NEUROLOGY, 2005, 57 (06) : 832 - 842
  • [23] MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  • [24] Meek PD, 1998, PHARMACOTHERAPY, V18, P68
  • [25] Advances in the early detection of Alzheimer's disease
    Nestor, PJ
    Scheltens, P
    Hodges, JR
    [J]. NATURE MEDICINE, 2004, 10 (07) : S34 - S41
  • [26] Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology
    Olsson, A
    Vanderstichele, H
    Andreasen, N
    De Meyer, G
    Wallin, A
    Holmberg, B
    Rosengren, L
    Vanmechelen, E
    Blennow, K
    [J]. CLINICAL CHEMISTRY, 2005, 51 (02) : 336 - 345
  • [27] Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment
    Pesaresi, Marzia
    Lovati, Carlo
    Bertora, Pierluigi
    Mailland, Enrico
    Galimberti, Daniela
    Scarpini, Elio
    Quadri, Pierluigi
    Forloni, Gianluigi
    Mariani, Claudio
    [J]. NEUROBIOLOGY OF AGING, 2006, 27 (06) : 904 - 905
  • [28] Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
    Petersen, RC
    Stevens, JC
    Ganguli, M
    Tangalos, EG
    Cummings, JL
    DeKosky, ST
    [J]. NEUROLOGY, 2001, 56 (09) : 1133 - 1142
  • [29] Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO
  • [30] 2-X